OptimizeRx Corp

OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OptimizeRx Corp exceeds revenue expectations, eyes growth through strategic deals

OptimizeRx Corp's strong revenue performance and focus on Real-World Data deals position them for growth despite challenges in revenue retention and operating expenses.
The company's strategic initiatives, including share repurchase, capacity utilization, and omnichannel expansion, showcase resilience and potential for market capture.
By leveraging RWD-AI models, focusing on strategic partnerships, and expanding service offerings, OptimizeRx aims to achieve financial and operational goals in 2023.

OptimizeRx Corp reports solid Q1 performance and eyes growth opportunities

OptimizeRx Corp (OPRX) reported solid Q1 performance, meeting revenue expectations and maintaining full-year outlook with a 10% YoY increase expected. The company showcased strengths in strategic partnerships, RWD-AI solutions, and effective use cases for RWE products.
Despite challenges in operating expenses and net revenue retention rate decline, the company is focused on innovation and growth opportunities through M&A, technology investments, and service expansion. By addressing challenges and leveraging opportunities, OptimizeRx Corp aims for sustainable growth and market differentiation.
With a strong emphasis on product execution, customer ROI, and shareholder value enhancement through a share repurchase program, OptimizeRx Corp is positioning itself for continued success in the healthcare technology sector. The company's strategic initiatives and focus on revenue diversification signal a promising outlook for future growth.

OptimizeRx Corp reports Q2 results, focuses on AI growth

OptimizeRx Corp navigated challenges in Q2 2023 with a focus on financial stability, operational efficiency, and strategic growth initiatives.
Despite disappointment with results, the company remains optimistic about the future of digital marketing in healthcare and the potential of AI-driven solutions.
With a strong balance sheet, emphasis on core business areas, and plans for cost management, OptimizeRx is positioned to capitalize on growth opportunities.
The company's commitment to renewals, upsells, and AI-driven engagement underscores a proactive approach to revenue retention and customer satisfaction.

OptimizeRx Corp (OPRX) beats Q3 expectations, eyes robust 2024 growth

OptimizeRx's Q3 performance exceeded expectations, showcasing strong financials and strategic acquisitions driving growth. While competitors face challenges, OptimizeRx is poised for further expansion and revenue increase in 2024 through enhanced platforms and market opportunities.

OptimizeRx Corp exceeds revenue expectations, eyes $100M target in 2024

OptimizeRx Corp delivered exceptional Q4 2023 results, driven by organic messaging strength and the Medicx Health acquisition.
The company's focus on digital solutions and strategic partnerships positions it well for future growth and capturing pharma spend.
While facing macroeconomic challenges, OptimizeRx's progress in Medicx Health integration and DAAP platform growth present promising opportunities.

OptimizeRx Corp reports robust Q1 performance, eyes sustained growth

OptimizeRx Corp's Q1 2024 performance reflects strong revenue growth, improved gross margin, and positive operating cash flow, underpinned by a focus on DAAP and stakeholder engagement.
While facing challenges in profitability and seasonality impact, the company remains optimistic about scaling DAAP, accelerating revenue growth, and enhancing performance in the second half of the year.
With opportunities to drive revenue through cross-selling, expanding infrastructure, and leveraging AI models, OptimizeRx is poised for sustainable growth and market leadership.

OptimizeRx Corp reports 30% revenue growth in Q3 2024

OptimizeRx Corp (OPRX) showcased strong revenue growth in Q3 2024, driven by HCP business performance.
While facing challenges in the DTC segment, the company is focused on enhancing customer relationships and operational efficiency.
With a positive outlook on growth and strategic initiatives in place, OptimizeRx Corp (OPRX) is poised for future success.
The company's emphasis on technological innovation and customer-centric approaches positions it well for industry advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Here's how OptimizeRx gets in front of physicians.

Why Would Doctors Use OptimizeRx?

OptimizeRx connects pharmaceutical companies directly with physicians.

This Healthcare Tech Stock Wants to Cut Out the Middleman

Camber Energy

Farmmi

Perrigo

Superior Drilling Products

These are some of the pre-market gainers to watch today. The post Pre-Market Gainers: SDPI, FAMI, CEI, PRGO, OPRX appeared first on Pulse 2.0.

Pre-Market Gainers: SDPI, FAMI, CEI, PRGO, OPRX

Doug Baker transitions to executive vice president of finance and accounting Doug Baker transitions to executive vice president of finance and accounting

OptimizeRx Appoints Seasoned Financial and Operational Executive, Edward Stelmakh as Chief Financial Officer and Chief Operations Officer

Lydall

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- OptimizeRx Corp. (NASD:OPRX) will replace Lydall Inc. (NYSE:LDL) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 4.

OptimizeRx Set to Join S&P SmallCap 600

Digital solutions provide new opportunities to support brand and HCP patient engagement challenges in survey of top U.S. endocrinologists Digital solutions provide new opportunities to support brand and HCP patient engagement challenges in survey of top U.S. endocrinologists

OptimizeRx Survey Demonstrates Value of Digital Solutions in Addressing Unmet Patient and Provider Needs in Diabetes

The Companies' combined point-of-care-engine creates an unmatched network of direct-to-physician digital interaction The Companies' combined point-of-care-engine creates an unmatched network of direct-to-physician digital interaction

OptimizeRx and Demandbase Form Exclusive Account-Based-Experience (ABX) Partnership — Delivering Industry's Most Powerful ABX Solution for Life Sciences

OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2021 Results - Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 42.86% and 10.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates

Shares of OptimizeRx (NASDAQ:OPRX) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 400.00% year over year to $0.10, which beat the estimate of $0.07.

OptimizeRx: Q2 Earnings Insights

- Revenue Up 55% to $13.6 million, closing on 19 enterprise contracts- Enterprise deals pipeline grows from 46 to 63 - Brands adopting OptimizeRx solutions increases to 140 from 80 in the past 6 months- Successful implementation of evidence-based provider engagement programs, driven by real-world evidence (“RWE”), anchored by sales from 2 leading brands - Cash flow positive from operations of $1.9 million in the first half of fiscal 2021

OptimizeRx Reports Second Quarter 2021 Financial Results, Revenue Up 55% as Leading Pharma Brands Aggressively Seek Improved ROI Through Technology Adoption

ROCHESTER, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Wednesday, August 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the second quarter, ended June 30, 2021. The financial results will be issued in a press release prior to the call.

OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET

OptimizeRx's AI-driven platform leverages real-world evidence (RWE) to support doctors in their efforts to maintain patient treatment plans OptimizeRx's AI-driven platform leverages real-world evidence (RWE) to support doctors in their efforts to maintain patient treatment plans

OptimizeRx Announces Agreement with a Top Pharmaceutical Manufacturer to Use its Evidence-Based Physician Engagement to Solve Lapse in Medical Coverage Barrier for Patients

Nano-X Imaging

OptimizeRx and Nano-X Imaging are two of my favorite small-caps right now. Here's why.

2 Top Small-Cap Stocks to Buy in July

OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OptimizeRx Corp. (OPRX) Upgraded to Strong Buy: Here's Why

Continued focus on building and closing pipeline of enterprise solutions across oncology, cardiology and immunology Continued focus on building and closing pipeline of enterprise solutions across oncology, cardiology and immunology

OptimizeRx Aligned With Pharma Across Fast Growing Specialty Therapeutic Areas

ROCHESTER, Mich., May 11, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will participate in RBC Capital Markets Global Healthcare Virtual Conference.

OptimizeRx to Present at RBC Capital Markets Global Virtual Healthcare Conference on May 19, 2021

OptimizeRx Corporation (OPRX) CEO William Febbo on Q1 2021 Results - Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 200.00% and 8.79%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Q1 Earnings and Revenues Beat Estimates

ROCHESTER, Mich., May 06, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported results for the three months ended March 31, 2021. Quarterly comparisons are to the same year-ago period.

OptimizeRx Reports First Quarter 2021 Financial Results, Revenue Up 48% on Rising Enterprise Adoption of Digital Health

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx Corp. (OPRX) Earnings Expected to Grow: Should You Buy?

ROCHESTER, Mich., April 28, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Thursday, May 6, 2021, at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. The financial results will be issued in a press release prior to the call.

OptimizeRx Sets First Quarter 2021 Conference Call for Thursday, May 6, 2021 at 4:30 p.m. ET

Several New Partnerships Expand Reach to Over 50% of Oncologists in the U.S. and Unlock Novel Touchpoints for Life Sciences to Engage Physicians Several New Partnerships Expand Reach to Over 50% of Oncologists in the U.S. and Unlock Novel Touchpoints for Life Sciences to Engage Physicians

OptimizeRx Expands Omni-channel Platform Reach at Point-Of-Care

OptimizeRx is an industry leader in providing digital health solutions for pharmaceutical companies, healthcare providers, and patients.

OptimizeRx Stock Is Just Getting Started

Ranked #277, highlighting the growth potential and convergence between technology and healthcare Ranked #277, highlighting the growth potential and convergence between technology and healthcare

News for OptimizeRx Corp Stock (OPRX)